Literature DB >> 11697754

Comparative pharmacokinetics and pharmacodynamics of amlodipine in hypertensive patients with and without type II diabetes mellitus.

R A Preston1, M Chung, M Gaffney, A Alonso, N M Baltodano, M Epstein.   

Abstract

Recent clinical trials aimed at attenuating complications in diabetes mellitus have generated interest in the impact of drug formulation and altered pharmacokinetics and pharmacodynamics in diabetes. Specifically, it has been proposed that the diabetic state may alter the pharmacokinetics of several cardiovascular drugs, including some calcium antagonists. The present study investigates the effects of diabetes mellitus on the pharmacokinetics and pharmacodynamics of amlodipine in hypertensive subjects with and without diabetes mellitus to determine whether the diabetic state alters these parameters. This trial consisted of a 2-week placebo washout phase, a 2-week titration phase, and a 2-week maintenance phase. Study patients included 18 hypertensive patients with type II diabetes mellitus and 10 nondiabetic hypertensive patients. Blood samples were collected after administration of amlodipine and AUC, Cmax, and tmax were determined. The acute 24-hour pharmacodynamic response to amlodipine was assessed by blood pressure and telemetric heart rate measurements. There were no significant differences for either amlodipine 5 or 10 mg in AUC (p = 0.40 for 5 mg; p = 0.59 for 10 mg), Cmax (p = 0.41 for 5 mg; p = 0.45 for 10 mg), and tmax (p = 0.79 for 5 mg; p = 0.67 for 10 mg) between diabetic and nondiabetic hypertensive subjects. Similarly, the 24-hour pharmacodynamic effects of amlodipine on systolic blood pressure, diastolic blood pressure, and heart rate did not differ between diabetic and nondiabetic subjects as assessed by repeated-measures analysis of variance. Because of the theoretical basis for anticipating that diabetes mellitus may provoke important pharmacokinetic and pharmacodynamic alterations, our study provides an important database in clearly demonstrating that the diabetic milieu did not alter the pharmacokinetics or pharmacodynamics of amlodipine.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11697754     DOI: 10.1177/00912700122012760

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  5 in total

1.  Transplacental Distribution of Lidocaine and Its Metabolite in Peridural Anesthesia Administered to Patients With Gestational Diabetes Mellitus.

Authors:  Elaine Christine Dantas Moises; Luciana de Barros Duarte; Ricardo de Carvalho Cavalli; Daniela Miarelli Carvalho; Gabriela Campos de Oliveira Filgueira; Maria Paula Marques; Vera Lucia Lanchote; Geraldo Duarte
Journal:  Reprod Sci       Date:  2015-01-05       Impact factor: 3.060

2.  Influence of gestational diabetes on the stereoselective pharmacokinetics and placental distribution of metoprolol and its metabolites in parturients.

Authors:  Natalícia de Jesus Antunes; Ricardo Carvalho Cavalli; Maria Paula Marques; Elaine Christine Dantas Moisés; Vera Lucia Lanchote
Journal:  Br J Clin Pharmacol       Date:  2015-04       Impact factor: 4.335

3.  Pharmacokinetics of lidocaine and its metabolite in peridural anesthesia administered to pregnant women with gestational diabetes mellitus.

Authors:  Elaine Christine Dantas Moisés; Luciana de Barros Duarte; Ricardo de Carvalho Cavalli; Maria Paula Marques; Vera Lúcia Lanchote; Geraldo Duarte; Sérgio Pereira da Cunha
Journal:  Eur J Clin Pharmacol       Date:  2008-08-06       Impact factor: 2.953

Review 4.  Effect of candesartan cilexetil on diabetic and non-diabetic hypertensive patients: meta-analysis of five randomized double-blind clinical trials.

Authors:  Ramzi E L Féghali; Sophie Nisse-Durgeat; Roland Asmar
Journal:  Vasc Health Risk Manag       Date:  2007

Review 5.  Plasma Trough Concentrations of Antihypertensive Drugs for the Assessment of Treatment Adherence: A Meta-Analysis.

Authors:  Eline H Groenland; Monique E A M van Kleef; Michiel L Bots; Frank L J Visseren; Kim C M van der Elst; Wilko Spiering
Journal:  Hypertension       Date:  2020-11-30       Impact factor: 10.190

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.